Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial

OBJECTIVES: We tested cytoplasmic HuR (cHuR) as a predictive marker for response to chemotherapy by examining tumor samples from the international European Study Group of Pancreatic Cancer-3 trial, in which patients with resected pancreatic ductal adenocarcinoma (PDA) received either gemcitabine (GE...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Surg
Hauptverfasser: Tatarian, Talar, Jiang, Wei, Leiby, Benjamin E., Grigoli, Amanda, Jimbo, Masaya, Dabbish, Nooreen, Neoptolemos, John P., Greenhalf, William, Costello, Eithne, Ghaneh, Paula, Halloran, Christopher, Palmer, Daniel, Buchler, Markus, Yeo, Charles J., Winter, Jordan M., Brody, Jonathan R.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815674/
https://ncbi.nlm.nih.gov/pubmed/27893535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/SLA.0000000000002088
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge